Founded in 1985, Yanke Xuebao (parallel title: Eye Science) (monthly, ISSN: 1000-4432; CN: 44-1119/R) is an international academic medical journal, governed by the Ministry of Education of the People's Republic of China, sponsored by Sun Yat-sen University, and published and distributed by the Zhongshan Ophthalmic Center, Sun Yat-sen University. Professor Haotian Lin (Zhongshan Ophthalmic Center, Sun Yat-sen University) holds the position of Editor-in-Chief, and Professor Zhenzhen Liu (Zhongshan Ophthalmic Center, Sun Yat-sen University) serves as Executive Editor-in-Chief. The editorial board consists of multiple distinguished ophthalmology experts from over 20 countries.

The journal has been included in multiple databases both in China and abroad, such as American Chemical Abstracts (CA), ICI Journals Master List, China National Knowledge Infrastructure (CNKI), Chinese Core Journals (Selection) Database (Wanfang), and Chinese Science and Technology Periodical Database (Chongqing VIP). It stands as an exemplar of innovative service for the "Professional Content & Knowledge Aggregation Service Platform", which is a national key research and development initiative.

Overview of Zhongshan Ophthalmic Center

Zhongshan Ophthalmic Center of Sun Yat-sen University is the only specialized ophthalmic hospital directly managed by the National Health Commission of China. It serves as the affiliated institution of the only National Key Laboratory for Ophthalmological Disease Prevention and Control. The Center is a national leader in ophthalmological innovation, making globally recognized contributions in areas such as regenerative ophthalmic medicine, bioinformatics, and medical artificial intelligence. Notably, the Center pioneered the in-situ regeneration of the lens using endogenous stem cells, a breakthrough published in Nature in 2016 and recognized by Nature Medicine as one of the "Top Eight Global Medical Advances" of the year, the first such honor for China's medical community. The research on myopia in adolescents received significant attention from President Jinping Xi, who issued an important directive in response. The Center's discovery that increased outdoor activities can effectively prevent myopia in adolescents was published in JAMA and has been incorporated into myopia prevention programs by both the World Health Organization (WHO) and Chinese government ministries. In addition, the Center has innovated in clinical applications of ophthalmic AI and successfully developed a new cataract drug, achieving a record-breaking technology transfer deal worth CNY 1.38 billion. The Center has won 11 National Science and Technology Progress Awards as the leading institution.

Zhongshan Ophthalmic Center is the most internationally influential ophthalmic institution in China. It is the only WHO collaborating center for ophthalmology in China and hosts the Asia-Pacific Academy of Ophthalmology, marking the first international medical academic organization based in Mainland China. The Center is also a member of ophthalmic research alliances in China, the UK, and the US.

Submission Turnaround Time:

Initial Review: 3 days

Peer Review: 2 weeks

Online Publication: Within 1-week post-acceptance

Formal Publication: Between 1 to 3 months post-acceptance, with original research articles receiving publication priority